Kuros Biosciences AG (SWX:KURN)
Switzerland · Delayed Price · Currency is CHF 22.88
+0.38 (1.69%)
Aug 4, 2026, 2:04 PM CET
Kuros Biosciences AG Revenue
In the year 2025, Kuros Biosciences AG had annual revenue of $146.06M USD with 71.51% growth. Kuros Biosciences AG had revenue of $82.58M in the half year ending December 31, 2025, with 223.38% growth.
Revenue
$146.06M
Revenue Growth
+71.51%
P/S Ratio
7.67
Revenue / Employee
$820.55K
Employees
178
Market Cap
887.82M CHF
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 146.06M | 60.90M | 71.51% |
| Dec 31, 2024 | 85.16M | 45.25M | 113.38% |
| Dec 31, 2023 | 39.91M | 20.46M | 105.15% |
| Dec 31, 2022 | 19.45M | 4.30M | 28.39% |
| Dec 31, 2021 | 15.15M | 10.66M | 237.01% |
| Dec 31, 2020 | 4.50M | 1.85M | 69.84% |
| Dec 31, 2019 | 2.65M | 1.92M | 264.23% |
| Dec 31, 2018 | 726.81K | 178.92K | 32.66% |
| Dec 31, 2017 | 547.90K | -494.55K | -47.44% |
| Dec 31, 2016 | 1.04M | 898.38K | 623.61% |
| Dec 31, 2015 | 144.06K | -862.63K | -85.69% |
| Dec 31, 2014 | 1.01M | -114.00K | -10.17% |
| Dec 31, 2013 | 1.12M | -81.17K | -6.75% |
| Dec 31, 2012 | 1.20M | -470.53K | -28.14% |
| Dec 31, 2011 | 1.67M | -22.24M | -93.01% |
| Dec 31, 2010 | 23.91M | 20.60M | 622.19% |
| Dec 31, 2005 | 3.31M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Roche Holding AG | 62.96B |
| Novartis AG | 45.81B |
| Lonza Group AG | 6.87B |
| Galderma Group AG | 4.16B |
| Aevis Victoria | 1.04B |
| PolyPeptide Group AG | 362.47M |
| SKAN Group AG | 333.34M |
| Medartis Holding AG | 269.26M |
Kuros Biosciences AG News
- 27 days ago - Kuros Biosciences initiated with a Buy at Berenberg - TheFly
- 6 weeks ago - Kuros Biosciences AG Transcript: CMD 2026 - Transcripts
- 6 weeks ago - Kuros Biosciences AG Press release: FY 2026 - Filings
- 6 weeks ago - Kuros Biosciences AG Slides: FY 2026 - Filings
- 6 weeks ago - Kuros Biosciences to showcase MagnetOs™ commercial momentum and plan for scalable quality growth at Capital Markets Day in Zürich - GlobeNewsWire
- 3 months ago - Kuros Biosciences appoints I.V. Hall as Chief Operating Officer, deepening operational, R&D and extremities leadership for next phase of growth - GlobeNewsWire
- 4 months ago - Kuros Biosciences reports 51% year-over-year increase in sales in the first three months of 2026 - GlobeNewsWire
- 4 months ago - Kuros Biosciences AG Earnings release: Q1 2026 - Filings